Please assess the completion status of the following clinical trial:

Trial Title: Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of essential hypertension, either treatment-naive or including currently on anti-hypertensive medication (in Italy only treatment naive patients) in whom it is medically justifiable to withdraw treatment , and who are likely to meet the required BP inclusion criteria at randomisation:~  * Mean sitting dBP ≥ 100 mmHg and ≤ 120 mmHg.~ * Mean sitting sBP ≥ 160 mmHg and ≤ 200 mmHg.~Main Exclusion Criteria:~* Mean sitting sBP values \> 200 mmHg and/or dBP \> 120 mmHg.~* Pregnant or nursing women.~* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the tested medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological, oncological, neurological, and psychiatric diseases. The same applies for immunocompromised and/or neutropenic patients.~* Patients with secondary hypertension of any aetiology such as renal disease, pheochromocytoma, or Cushing's syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OM 40 (Type: ACTIVE_COMPARATOR): Olmesartanmedoxomil (OM)40 mg tablets.
- OM/HCTZ 40/12.5 (Type: EXPERIMENTAL): Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).